Dipak Patel

DGM QC at Intas Pharmaceuticals Limited, Fermentation Division, Ankleshwar

Role: Dgm Quality Control at Intas Pharmaceuticals
Location: Bharuch, GJ, IN
LinkedIn followers: 500 followers

OtherView LinkedIn profile

About Dipak Patel

Faced TGA Audit held on September-2013 and got Approval for Product: Exemestane Faced…

Experience

Dgm Quality Control
Intas Pharmaceuticals
Apr 2024 — Present

Education

Gujarat University
Bachelor of Science (B.Sc.)
1995 — 1997
Gujarat University
Master of Science (M.Sc.)
1997 — 1999

Skills

Capa
Equipment Qualification
Regulatory Requirements
Quality System
Standard Operating Procedure (Sop)
Change Control
Validation
Corrective and Preventive Action (Capa)
High-Performance Liquid Chromatography (Hplc)
Gmp
Pharmaceutical Industry
Sop
Fda
21 Cfr Part 11
Hplc
Glp
U.s. Food and Drug Administration (Fda)
Good Laboratory Practice (Glp)

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@intaspharma.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Intas Pharmaceuticals

Pharmaceutical Manufacturing · 20K employees · Ahmedabad, Gujarat, India

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

intaspharma.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.